Short answer: The exact manufacturing cost of Humira (adalimumab) is not publicly disclosed by the company. Details of cost of goods sold (COGS) for specific biologics are proprietary.
What’s generally true:
- Humira is a monoclonal antibody produced in mammalian (CHO) cell culture, with extensive purification, formulation, sterile filling, quality control, and cold-chain shipping. Those steps drive the cost.
- Industry estimates for the cost to produce a single 40 mg dose of a monoclonal antibody typically fall in the low hundreds of dollars per dose, though figures vary by scale, facility, and efficiency.
A rough way to think about it:
- Typical Humira dosing for many conditions is 40 mg every two weeks (about 26 doses per year).
- If the cost of goods per 40 mg dose were around, say, $100–$400, the annual manufacturing cost per patient would be roughly $2,600–$10,400.
- The actual list price to patients is much higher (often on the order of tens of thousands of dollars per year), because pricing also covers development, regulatory costs, marketing, distribution, rebates, and profit.
If you want, I can tailor a quick calculation for you based on:
- a specific dosing schedule (e.g., 40 mg weekly vs every other week),
- an assumed cost per 40 mg dose (e.g., $150, $250, $350),
- or a per-dose vs per-year perspective.